SG11201908181XA - Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof - Google Patents
Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereofInfo
- Publication number
- SG11201908181XA SG11201908181XA SG11201908181XA SG11201908181XA SG 11201908181X A SG11201908181X A SG 11201908181XA SG 11201908181X A SG11201908181X A SG 11201908181XA SG 11201908181X A SG11201908181X A SG 11201908181XA
- Authority
- SG
- Singapore
- Prior art keywords
- malvern
- pennsylvania
- international
- rule
- spring mill
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title abstract 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Medicinal Preparation (AREA)
Abstract
JI l a Jul () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) W I PO I PC T IiiimmoimiolollmonolomommoolinioniovoimIE (10) International Publication Number WO 2018/165048 Al (51) International Patent Classification: A61K 31/69 (2006.01) A61P 31/04 (2006.01) A61K 31/546 (2006.01) (21) International Application Number: PCT/US2018/020968 (22) International Filing Date: 05 March 2018 (05.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/467,750 06 March 2017 (06.03.2017) US 62/467,752 06 March 2017 (06.03.2017) US 62/564,989 28 September 2017 (28.09.2017) US 62/564,990 28 September 2017 (28.09.2017) US (71) Applicant: VENATORX PHARMACEUTICALS, INC. [US/US]; 30 Spring Mill Drive, Malvern, Pennsylvania 19355 (US). (72) Inventors: BURNS, Christopher J.; 30 Spring Mill Dri- ve, Malvern, Pennsylvania 19355 (US). PEVEAR, Daniel C.; 30 Spring Mill Drive, Malvern, Pennsylvania 19355 (US). XERRI, Luigi; 30 Spring Mill Drive, Malvern, Pennsylvania 19355 (US). HENKEL, Timothy; 30 Spring Mill Drive, Malvern, Pennsylvania 19355 (US). MCGAR- RY, Daniel; 30 Spring Mill Drive, Malvern, Pennsylva- nia 19355 (US). ROSEN, Lawrence; 30 Spring Mill Dri- ve, Malvern, Pennsylvania 19355 (US). BRENNER, Ger- ald; 3007 Oakwood Drive, Plymouth Meeting, Pennsylva- nia 19462 (US). ARLIN, Jean-Baptiste; Meibergdreef 31, 1105 AZ Amsterdam (NL). FERNANDEZ CASARES, Ana; Meibergdreef 31, 1105 AZ Amsterdam (NL). (74) Agent: HARDT, Ingo H.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF FIG. 2 GC 71' O 00 0 (57) : Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hy- droxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for O treating a subject in need thereof with a bacterial infection. [Continued on next page] WO 2018/165048 Al MIDEDIMOMOIDEIREEMOMMEMINNIEHIMMIS SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762467752P | 2017-03-06 | 2017-03-06 | |
US201762467750P | 2017-03-06 | 2017-03-06 | |
US201762564989P | 2017-09-28 | 2017-09-28 | |
US201762564990P | 2017-09-28 | 2017-09-28 | |
PCT/US2018/020968 WO2018165048A1 (en) | 2017-03-06 | 2018-03-05 | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908181XA true SG11201908181XA (en) | 2019-10-30 |
Family
ID=63448038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908181X SG11201908181XA (en) | 2017-03-06 | 2018-03-05 | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (3) | US11091505B2 (en) |
EP (1) | EP3592362A4 (en) |
JP (2) | JP2020510661A (en) |
KR (1) | KR102603489B1 (en) |
CN (2) | CN117398398A (en) |
AU (1) | AU2018230991B2 (en) |
BR (1) | BR112019018447A2 (en) |
CA (1) | CA3055253A1 (en) |
IL (2) | IL301591A (en) |
MA (1) | MA47743A (en) |
MY (1) | MY196966A (en) |
PH (1) | PH12019502037A1 (en) |
SG (1) | SG11201908181XA (en) |
WO (1) | WO2018165048A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014089365A1 (en) | 2012-12-07 | 2014-06-12 | Venatorx Pharmaceuticals, Inc | Beta-lactamase inhibitors |
WO2014110442A1 (en) | 2013-01-10 | 2014-07-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
ES2874579T3 (en) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
CN108472284A (en) | 2015-09-11 | 2018-08-31 | 维纳拓尔斯制药公司 | Beta-lactamase inhibitor |
WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
WO2018027062A1 (en) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
AU2018230991B2 (en) | 2017-03-06 | 2023-07-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
CN110959008A (en) | 2017-05-26 | 2020-04-03 | 维纳拓尔斯制药公司 | Penicillin binding protein inhibitors |
CN113015532B (en) | 2018-09-12 | 2024-03-15 | 维纳拓尔斯制药公司 | Combination compositions comprising beta-lactamase inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1021454A (en) | 1911-01-23 | 1912-03-26 | Thomas Ernest Davis | Serving-table. |
US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
ES2457593T3 (en) | 2004-03-30 | 2014-04-28 | Millennium Pharmaceuticals, Inc. | Bortezomib synthesis |
CN1965838A (en) | 2005-11-17 | 2007-05-23 | 李海超 | Pharmaceutical composition containing cefpiramide and beta-lactamase inhibitor |
CN101129382B (en) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | Antibiotic compound containing beta-lactam antibiotic and buffering component |
US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
AR069310A1 (en) | 2007-11-13 | 2010-01-13 | Protez Pharmaceuticals Inc | BETA-LACTAMASA INHIBITORS |
UA101966C2 (en) | 2008-01-18 | 2013-05-27 | Мерк Шарп Енд Доме Корп. | Beta-lactamase inhibitors |
US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
ES2789177T3 (en) | 2010-08-10 | 2020-10-26 | Melinta Therapeutics Inc | Cyclic boronic acid ester derivatives, process for their preparation and therapeutic uses thereof |
EP2768503A1 (en) * | 2011-07-26 | 2014-08-27 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
KR101288157B1 (en) | 2011-12-07 | 2013-07-19 | 백병하 | A Combined antibiotics comprising cepha antibiotics and beta-lactamase inhibitor |
JP5798495B2 (en) | 2012-01-13 | 2015-10-21 | 住友理工株式会社 | Wiring body connection structure |
EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
DE102012101680A1 (en) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmaceutical preparation containing an antiviral dihydroquinazoline derivative |
WO2014089365A1 (en) | 2012-12-07 | 2014-06-12 | Venatorx Pharmaceuticals, Inc | Beta-lactamase inhibitors |
CA2894891A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
AU2014204046B2 (en) | 2013-01-04 | 2017-02-23 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
WO2014110442A1 (en) | 2013-01-10 | 2014-07-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
WO2015157618A1 (en) | 2014-04-11 | 2015-10-15 | The Texas A&M University System | Novel inhibitors of the new delhi metallo beta lactamase (ndm-1) |
US20150361107A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
ES2874579T3 (en) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
KR101935186B1 (en) | 2014-09-04 | 2019-01-03 | 시오노기세야쿠 가부시키가이샤 | Pharmaceutical preparation comprising cephalosporin having catechol groups |
ES2761778T3 (en) | 2014-12-19 | 2020-05-21 | Rempex Pharmaceuticals Inc | Continuous flow apparatus and process for the production of boronic acid derivatives |
CN108472284A (en) | 2015-09-11 | 2018-08-31 | 维纳拓尔斯制药公司 | Beta-lactamase inhibitor |
CN105801610B (en) | 2016-04-19 | 2018-05-18 | 武汉维舜医药科技有限公司 | New-type wide-spectrum beta-lactamase inhibitor |
ES2894251T3 (en) | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Boronic acid derivatives and therapeutic uses thereof |
WO2018027062A1 (en) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
AU2018230991B2 (en) | 2017-03-06 | 2023-07-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
EP3802551A4 (en) | 2018-05-25 | 2022-03-02 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
CN113015532B (en) | 2018-09-12 | 2024-03-15 | 维纳拓尔斯制药公司 | Combination compositions comprising beta-lactamase inhibitors |
MA54319A (en) | 2018-11-29 | 2021-10-06 | Venatorx Pharmaceuticals Inc | MIXED COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND THEIR USES |
-
2018
- 2018-03-05 AU AU2018230991A patent/AU2018230991B2/en active Active
- 2018-03-05 WO PCT/US2018/020968 patent/WO2018165048A1/en unknown
- 2018-03-05 CN CN202311312855.3A patent/CN117398398A/en active Pending
- 2018-03-05 KR KR1020197029086A patent/KR102603489B1/en active IP Right Grant
- 2018-03-05 IL IL301591A patent/IL301591A/en unknown
- 2018-03-05 MY MYPI2019005139A patent/MY196966A/en unknown
- 2018-03-05 CN CN201880030083.5A patent/CN110678186A/en active Pending
- 2018-03-05 JP JP2019547093A patent/JP2020510661A/en active Pending
- 2018-03-05 IL IL268981A patent/IL268981B2/en unknown
- 2018-03-05 SG SG11201908181X patent/SG11201908181XA/en unknown
- 2018-03-05 MA MA047743A patent/MA47743A/en unknown
- 2018-03-05 US US16/491,116 patent/US11091505B2/en active Active
- 2018-03-05 CA CA3055253A patent/CA3055253A1/en active Pending
- 2018-03-05 BR BR112019018447A patent/BR112019018447A2/en unknown
- 2018-03-05 EP EP18763383.9A patent/EP3592362A4/en active Pending
-
2019
- 2019-09-06 PH PH12019502037A patent/PH12019502037A1/en unknown
-
2021
- 2021-06-21 US US17/353,377 patent/US11820784B2/en active Active
-
2023
- 2023-01-20 JP JP2023007546A patent/JP2023061946A/en active Pending
- 2023-09-27 US US18/476,050 patent/US20240101580A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3592362A1 (en) | 2020-01-15 |
IL268981A (en) | 2019-10-31 |
CN117398398A (en) | 2024-01-16 |
CA3055253A1 (en) | 2018-09-13 |
KR102603489B1 (en) | 2023-11-16 |
IL301591A (en) | 2023-05-01 |
JP2023061946A (en) | 2023-05-02 |
EP3592362A4 (en) | 2020-09-02 |
WO2018165048A1 (en) | 2018-09-13 |
MY196966A (en) | 2023-05-15 |
BR112019018447A2 (en) | 2020-04-14 |
US11091505B2 (en) | 2021-08-17 |
AU2018230991A1 (en) | 2019-09-19 |
CN110678186A (en) | 2020-01-10 |
PH12019502037A1 (en) | 2020-03-09 |
IL268981B2 (en) | 2023-09-01 |
US20200010485A1 (en) | 2020-01-09 |
MA47743A (en) | 2020-01-15 |
IL268981B1 (en) | 2023-05-01 |
JP2020510661A (en) | 2020-04-09 |
AU2018230991B2 (en) | 2023-07-13 |
US11820784B2 (en) | 2023-11-21 |
KR20190117790A (en) | 2019-10-16 |
US20240101580A1 (en) | 2024-03-28 |
US20220002322A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908181XA (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
SG11201807998WA (en) | Treatment Of Inflammatory Diseases With Inhibitors Of C5a Activity | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
SG11201811189RA (en) | Variant adeno-associated viruses and methods of using | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201805217XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11202000145XA (en) | Methods and systems for conditionally regulating gene expression | |
SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
SG11201910198UA (en) | Multibiotic agents and methods of using the same | |
SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
SG11201908088RA (en) | Antibodies against pd-l1 | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201900464TA (en) | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) | |
SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
SG11201809751XA (en) | Egfr inhibitor compounds |